Tempus

Tempus was founded in 2015 by Eric Lefkofsky, a co-founder of Groupon, following his own family's experience navigating cancer treatment, which motivated him to apply large-scale data analytics and genomic sequencing technology to help physicians make more personalized, data-driven treatment decisions for cancer and other complex diseases, based on the observation that even as genomic sequencing technology had become more accessible and affordable, translating a patient's specific genomic and molecular tumor characteristics into concrete, actionable treatment recommendations still required synthesizing an enormous amount of complex clinical and scientific information that individual physicians, however skilled, often struggled to fully incorporate into treatment decisions given the rapidly expanding volume of relevant precision medicine research and treatment options. Tempus's platform combines genomic and molecular sequencing of patient tumor samples with a very large proprietary database of de-identified clinical and outcomes data from other patients, using this combined data to help identify which specific treatments, including targeted therapies and immunotherapies, are most likely to be effective for a given patient's specific molecular tumor profile, and to help identify patients who might be good candidates for specific clinical trials studying experimental treatments relevant to their particular cancer's molecular characteristics. The company has expanded significantly beyond its original oncology focus into additional disease areas including cardiology and other complex conditions where genomic and data-driven precision medicine approaches offer similar potential to improve treatment personalization. Tempus has built a large proprietary clinico-genomic dataset, combining molecular sequencing data with de-identified clinical outcomes information, a dataset the company has also licensed to pharmaceutical companies for drug development research purposes in addition to using it to support direct clinical decision support for treating physicians. The company went public via a traditional initial public offering on Nasdaq in 2024. Tempus has raised substantial private funding over its history from investors including Baillie Gifford, Franklin Templeton, and Google, prior to and following its public listing, competing with other precision medicine and genomic testing companies including Foundation Medicine and Guardant Health.

News

10/23/2026

Tempus and Bristol Myers Squibb Expand Oncology Data Collaboration

Tempus enhances its partnership with Bristol Myers Squibb to license oncology data, leveraging AI to improve drug discovery and patient outcomes.

Yahoo Finance

10/20/2026

Tempus AI Faces Revenue Risks Amid AstraZeneca Licensing Deal

Despite a 22% sales growth, Tempus AI's stock declines 17.3% due to uncertainties surrounding its data licensing agreement with AstraZeneca, which significantly impacts future revenue.

Yahoo Finance

10/5/2026

Tempus AI Stock Rises 9.03% After FDA Clearance for ECG Tool

Tempus AI's stock surges following FDA clearance for its Tempus ECG-MR tool, despite concerns over its current valuation and a recent decline in shareholder returns.

Yahoo Finance

9/15/2026

Tempus Founder Backs Anthropic CEO's Call for AI Development Slowdown

Tempus Ai's founder endorses the need for a slowdown in AI advancements, highlighting rising safety concerns within the industry.

TradingView

9/14/2026

Tempus Secures $9.5 Million to Develop Autonomous AI for Cardiology

Tempus receives $9.5 million from ARPA-H to create an autonomous AI agent aimed at improving cardiovascular care amid a cardiologist shortage in the U.S.

Yahoo Finance